Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHV NASDAQ:CDXS NASDAQ:DOMH NASDAQ:SABS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHVAchieve Life Sciences$5.21+8.8%$3.95$2.00▼$6.03$254.99M2.251.85 million shs1.76 million shsCDXSCodexis$2.85+10.5%$1.90$0.96▼$3.87$234.51M2.521.33 million shs1.83 million shsDOMHDominari$3.64+10.6%$3.00$2.68▼$8.40$74.40M0.6994,509 shs319,427 shsSABSSAB Biotherapeutics$4.11+0.5%$3.88$1.60▼$6.60$208.39M0.55602,197 shs6.01 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHVAchieve Life Sciences0.00%+9.11%+46.93%+12.71%+101.26%CDXSCodexis0.00%-8.51%+16.74%+93.98%+13.16%DOMHDominari0.00%+14.24%+14.24%-11.80%-40.61%SABSSAB Biotherapeutics0.00%+9.36%+9.65%-1.92%+142.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHVAchieve Life Sciences$5.21+8.8%$3.95$2.00▼$6.03$254.99M2.251.85 million shs1.76 million shsCDXSCodexis$2.85+10.5%$1.90$0.96▼$3.87$234.51M2.521.33 million shs1.83 million shsDOMHDominari$3.64+10.6%$3.00$2.68▼$8.40$74.40M0.6994,509 shs319,427 shsSABSSAB Biotherapeutics$4.11+0.5%$3.88$1.60▼$6.60$208.39M0.55602,197 shs6.01 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHVAchieve Life Sciences0.00%+9.11%+46.93%+12.71%+101.26%CDXSCodexis0.00%-8.51%+16.74%+93.98%+13.16%DOMHDominari0.00%+14.24%+14.24%-11.80%-40.61%SABSSAB Biotherapeutics0.00%+9.36%+9.65%-1.92%+142.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHVAchieve Life Sciences 3.00Buy$14.67181.51% UpsideCDXSCodexis 2.00Hold$5.0075.44% UpsideDOMHDominari 1.00SellN/AN/ASABSSAB Biotherapeutics 2.63Moderate Buy$10.50155.47% UpsideCurrent Analyst Ratings BreakdownLatest DOMH, ACHV, CDXS, and SABS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026ACHVAchieve Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026ACHVAchieve Life Sciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$13.004/20/2026ACHVAchieve Life Sciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/16/2026ACHVAchieve Life Sciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/10/2026SABSSAB Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)4/2/2026SABSSAB Biotherapeutics Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$13.003/27/2026ACHVAchieve Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/25/2026ACHVAchieve Life Sciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.003/12/2026CDXSCodexis Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$5.003/12/2026CDXSCodexis Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight3/12/2026SABSSAB Biotherapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHVAchieve Life SciencesN/AN/AN/AN/A$0.40 per shareN/ACDXSCodexis$70.39M3.68N/AN/A$0.56 per share5.09DOMHDominari$123.10M0.67N/AN/A$4.28 per share0.85SABSSAB Biotherapeutics$1.32M158.64$0.34 per share11.97$3.18 per share1.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHVAchieve Life Sciences-$54.65M-$1.30N/AN/AN/AN/A-204.14%-121.36%5/12/2026 (Estimated)CDXSCodexis-$43.97M-$0.37N/AN/AN/A-40.97%-66.32%-23.41%N/ADOMHDominari-$22.43M-$3.88N/AN/AN/A-18.22%-176.52%-145.57%5/13/2026 (Estimated)SABSSAB Biotherapeutics$13.27M-$2.32N/AN/AN/AN/A15.17%12.51%5/12/2026 (Estimated)Latest DOMH, ACHV, CDXS, and SABS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026N/ADOMHDominari-$0.17N/AN/AN/A$30.08 millionN/A5/12/2026Q1 2026ACHVAchieve Life Sciences-$0.30N/AN/AN/AN/AN/A5/12/2026Q1 2026SABSSAB Biotherapeutics-$0.2125N/AN/AN/A$0.13 millionN/A5/7/2026Q1 2026CDXSCodexis-$0.11-$0.10+$0.01-$0.10$14.53 million$15.25 million3/24/2026Q4 2025ACHVAchieve Life Sciences-$0.27-$0.28-$0.01-$0.28N/AN/A3/11/2026Q4 2025CDXSCodexis$0.01$0.11+$0.10$0.11$35.83 million$38.92 million3/9/2026Q4 2025SABSSAB Biotherapeutics-$0.16-$0.46-$0.30-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACHVAchieve Life SciencesN/AN/AN/AN/AN/ACDXSCodexisN/AN/AN/AN/AN/ADOMHDominariN/AN/AN/AN/AN/ASABSSAB BiotherapeuticsN/AN/AN/AN/AN/ALatest DOMH, ACHV, CDXS, and SABS DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/4/2026DOMHDominarispecial$0.315/15/20265/15/20265/29/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHVAchieve Life Sciences0.524.394.39CDXSCodexis0.793.823.75DOMHDominariN/A2.492.49SABSSAB Biotherapeutics0.029.469.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHVAchieve Life Sciences33.52%CDXSCodexis78.54%DOMHDominari42.48%SABSSAB Biotherapeutics7.82%Insider OwnershipCompanyInsider OwnershipACHVAchieve Life Sciences3.00%CDXSCodexis1.90%DOMHDominari55.30%SABSSAB Biotherapeutics25.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHVAchieve Life Sciences2053.23 million51.64 millionOptionableCDXSCodexis25090.90 million89.17 millionOptionableDOMHDominari422.61 million10.11 millionNot OptionableSABSSAB Biotherapeutics14050.95 million38.18 millionNot OptionableDOMH, ACHV, CDXS, and SABS HeadlinesRecent News About These CompaniesSAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ETMay 5, 2026 | globenewswire.comSAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 3, 2026 | americanbankingnews.comSAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Average Rating of "Moderate Buy" by BrokeragesMay 3, 2026 | marketbeat.comSAB Biotherapeutics (SABS) Expected to Announce Earnings on FridayMay 1, 2026 | marketbeat.comShort Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Expands By 19.8%April 30, 2026 | marketbeat.comSAB Biotherapeutics (NASDAQ:SABS) Shares Down 1.4% - Here's What HappenedApril 30, 2026 | marketbeat.comEmergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB ...April 29, 2026 | caledonianrecord.comCSAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026April 22, 2026 | globenewswire.comSAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 DiabetesApril 15, 2026 | seekingalpha.comSAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society CongressApril 15, 2026 | markets.businessinsider.comSAB Biotherapeutics closes $85 million public offeringMarch 20, 2026 | thepharmaletter.comTSAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded WarrantsMarch 19, 2026 | globenewswire.comSAB Biotherapeutics Launches Major Equity Financing OfferingMarch 19, 2026 | tipranks.comSAB Biotherapeutics, Inc. Prices Public Offering of Common Stock and Pre-Funded Warrants to Raise Approximately $85 MillionMarch 17, 2026 | quiverquant.comQSAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded WarrantsMarch 17, 2026 | globenewswire.comSAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsMarch 17, 2026 | globenewswire.comSAB Biotherapeutics Highlights New Phase 1 SAB-142 DataMarch 10, 2026 | tipranks.comSAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 DiabetesMarch 10, 2026 | globenewswire.comSAB BIO Reports Full Year 2025 Financial Results and Business HighlightsMarch 9, 2026 | globenewswire.comSAB BIO to Participate in Upcoming Investor ConferencesMarch 2, 2026 | globenewswire.comSAB BIO to Participate in Upcoming Investor ConferencesFebruary 4, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDOMH, ACHV, CDXS, and SABS Company DescriptionsAchieve Life Sciences NASDAQ:ACHV$5.21 +0.42 (+8.77%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$5.23 +0.02 (+0.46%) As of 05/8/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.Codexis NASDAQ:CDXS$2.85 +0.27 (+10.47%) As of 05/8/2026 04:00 PM EasternCodexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Dominari NASDAQ:DOMH$3.64 +0.35 (+10.64%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$3.75 +0.11 (+2.91%) As of 05/8/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.SAB Biotherapeutics NASDAQ:SABS$4.11 +0.02 (+0.49%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$4.32 +0.21 (+5.11%) As of 05/8/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
